Non-CFC Albuterol Transition Cost Increase Could Affect Patient Access, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Low-income patients will bear the burden of increased costs of transition from CFC albuterol to non-ozone depleting formulations, committee member says. GSK sampling and patient assistance programs are aimed at lessening burden. Longer transition period could allow introduction of competitors/generics, committee member suggests.
You may also be interested in...
Atrovent HFA Approval Breathes New Life Into Boehringer Ingelheim's Brand
The CFC-free version of the bronchodilator will receive three years of labeling exclusivity. FDA action to move ozone-depleting products off the market could remove BI's generic Atrovent competition.
Atrovent HFA Approval Breathes New Life Into Boehringer Ingelheim's Brand
The CFC-free version of the bronchodilator will receive three years of labeling exclusivity. FDA action to move ozone-depleting products off the market could remove BI's generic Atrovent competition.
Ivax CFC-Free Albuterol Will Launch In Fourth Quarter
FDA cleared the NDA for the asthma treatment Oct. 29. Ivax’ CFC-free albuterol inhaler offers an alternative to GlaxoSmithKline’s Ventolin HFA in advance of an FDA final rule that is expected to remove CFC-propelled albuterol from the market in 2006.